0
Obstructive Lung Diseases |

Role of Indacaterol in the Treatment of COPD FREE TO VIEW

Raja Dhar, MD; Sanjit Ray Chaudhuri
Author and Funding Information

Fortis hospital, Kolkata, India


Chest. 2014;145(3_MeetingAbstracts):387A. doi:10.1378/chest.1836357
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Posters

SESSION TYPE: Poster Presentations

PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM

PURPOSE: Indacaterol is an ultra-long-acting beta-adrenoceptor agonist which needs to be taken once a day, licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler. A year-long, placebo-controlled trial published in July 2010 suggests indacaterol may be significantly more effective than twice-daily formoterol in improving FEV1. There were some reductions in the need for rescue medication, but these were not significantly different; nor was there any difference in the rate of exacerbation between the 2 active treatments. We looked at our data regarding the use of Indacaterol in a tertiary care set up. This is a real life experience looking at how Indacaterol influences clinical (MRC dyspnoea scale) and physiological (Spirometry) parameters and exacerbation episodes.

METHODS: We did a prospective study looking at the use of Indacaterol in 50 consecutive patients. It could be used in conjunction with other medications for COPD. The patients should have been on Indacaterol for at least 3 months. We looked at all parameters including Spirometry, MRC dyspnoea scale, use of rescue medications, exacerbations (use of oral steroids, emergency visits, hospitalisation and ventilation) and 6 minute walk test.

RESULTS: 76% of our patients were men with a mean age of 67.3±8.6 years. The patients were on Indacaterol for a mean of 136 days. Use of Indacaterol showed significant improvement in Spirometry, 6 minute walk test and MRC dyspnoea scale. It also showed significant reduction in use of rescue medications and all exacerbations. The medication was also shown to be well tolerated with minimal side-effects.

CONCLUSIONS: Indacaterol is a useful adjunct to standard treatment for COPD causing significant improvement in clinical and physiological parameters. We need further longitudinal studies to establish its long-term efficacy.

CLINICAL IMPLICATIONS: This study provides evidence for the usefulness of the newest Long acting Beta agonist (LABA) in day to day clinical practice. The improved results we have obtained (compared to available RCTs) is because the drug has been used in conjunction with other available agents for stable COPD. This shows its relevance in routine clinical practice where multiple agents are usually combined together for moderate to severe disease and also underlines the importance of using bronchodilators as first line for stable COPD as recommended by the GOLD guidelines.

DISCLOSURE: The following authors have nothing to disclose: Raja Dhar, Sanjit Ray Chaudhuri

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543